Focus: Ekso Bionics designs and commercializes wearable robotic exoskeletons for spinal cord injury rehabilitation and mobility assistance. The company is a publicly traded medical device innovator focused on restoring movement and independence.
Profile data last refreshed 13h ago · AI intelligence enriched 2d ago
No open roles listed right now. Follow Ekso Bionics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Ekso Bionics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Ekso Bionics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Wandercraft acquires Ekso Bionics to build global exoskeleton leader - Dealroom
Wandercraft acquires Ekso Bionics to build global exoskeleton leader Dealroom
Sarcomatrix Therapeutics Extends Accredited Investor Round to October 31 - The Manila Times
Sarcomatrix Therapeutics Extends Accredited Investor Round to October 31 The Manila Times
Wandercraft Acquires Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility - The Manila Times
Wandercraft Acquires Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility The Manila Times
8-K Filing: ChronoScale Holdings Corp (CHRN) (CIK 0001549084) — EX-10.1
EX-10.1
NuvOx Therapeutics, Clinical-Stage Oxygen Therapeutics Developer, Files for NYSE American IPO - TradingView
NuvOx Therapeutics, Clinical-Stage Oxygen Therapeutics Developer, Files for NYSE American IPO TradingView
Ekso Bionics Holdings Stock (US2826641040): Ticker Change To ChronoScale Raises Questions For Legacy - AD HOC NEWS
Ekso Bionics Holdings Stock (US2826641040): Ticker Change To ChronoScale Raises Questions For Legacy AD HOC NEWS
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Walking improvement in chronic incomplete spinal cord injury with exoskeleton robotic training (WISE): a randomized controlled trial.
Comparison of peak oxygen consumption response to aquatic and robotic therapy in individuals with chronic motor incomplete spinal cord injury: a randomized controlled trial.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo